Kalypsys and NovImmune Establish Collaboration for Discovery and Development of New Drugs for Autoimmune and Inflammatory Diseases

NovImmune will partner most of its antibody
drugs after completion of phase II clinical trials. NovImmune has
concluded 10 biotech alliances, giving the company access to key technologies
required to implement its drug development program.com. In return, Cytos Biotechnology will receive an upfront payment,
and has the opportunity to earn license fees, milestones, and royalties on net
sales of products that are successfully brought to market. Medarex disclaims, however, any intent or obligation to update
these forward-looking statements .

transgenic detrimental

and NovImmune
SA announced today a collaboration designed to accelerate the discovery and
development of new drugs for autoimmune and inflammatory diseases., Chief Scientific Officer of
NovImmune.medarex .

oligos sandoz

Under terms of this new agreement, Medarex will acquire the exclusive
rights to develop and commercialize monoclonal antibody therapeutics against
the collaboration targets.

polypeptides ibt

Financial
terms of the agreement were not disclosed. Kalypsys has announced other
technology transfer partnerships with Merck + Co.7141

Euro RSCG Life NRP:
Holli Kolkey
Phone: +1., Cytos Biotechnology AG (SWX: CYTN) and Medarex, Inc.

For Cytos Biotechnology AG: This foregoing press release may contain
forward-looking statements that include words or phrases such as "will," "has
the opportunity to," "gives the opportunity to," "designed to," "intend," or
other similar expressions.S.

ligands biosensors

Kalypsys uses its technologies and sizeable drug -like compound
collection to improve the drug discovery research process and generate a
robust pipeline for itself and its partners. Food and Drug Administration or equivalent regulatory
authorities , or that drugs will be marketed successfully.

commercializing scigenics

The
collaboration will pair Kalypsys' 1536-well ultra -high throughput screening
technology, extensive chemical library and small molecule research
capabilities with NovImmune's expertise in immunoregulation and MHC class II
associated biology. Autoimmune and inflammatory disorders represent a large
group of diseases that are due to aberrant activation of T lymphocytes."
In the collaboration, Kalypsys will screen its proprietary library to
identify potent modulators of MHC class II and establish a chemical profile of
the target using its ultra -high throughput automated technology and
informatics.22.858.
The identification of disease -relevant drug targets is a key first step in
successful drug development. Medarex applies its UltiMAb (R) technology
and product development and clinical manufacturing experience to generate,
support and potentially commercialize a broad range of fully human antibody
products for itself and its partners .

sandoz limulus

"We look forward to exploiting opportunistic leads that emerge
using NovImmune's proprietary assays as well as those that specifically target
the transcription factors regulating MHC class II molecules . Kalypsys' mission is to build a
sustainable drug candidate pipeline from target to proof of efficacy and
safety in the clinic with unmatched speed, efficiency, and success rates and
currently has a pre-clinical pipeline of small molecule candidates which is
advancing rapidly to clinical development . For more
information on Kalypsys, please visit http://www.kolkey@eurorscg.J. Cytos Biotechnology 's protein discovery
technology DELphi(TM) aims at representative production of the proteins
encoded by the human genome in a functionally active form and has led to
discovery of several disease proteins of potential relevance in major chronic
diseases, such as atherosclerosis. Statements that are not historical
facts, including statements preceded by, followed by, or that include the
words "potential; " "believe;" "anticipate;" "intend;" "plan;" "expect;"
"estimate;" "could;" "may;" or similar statements are forward-looking
statements.

Pharmaceuticals include over-the-counter and prescription medications , vitamins and nutritional supplements.

polypeptides vaccinating

Director, Business Development
Phone: +1.
Chief Executive Officer
Phone: +41. Taking
advantage of the high flexibility of its Immunodrug(TM) platform, Cytos
Biotechnology has built a pipeline of 27 different Immunodrug(TM) candidates
in various disease areas, of which five are currently in clinical development.

sigrist recombinant

SAN DIEGO and GENEVA, Kalypsys, Inc.
The collaboration is intended to discover, develop and commercialize small
molecule modulators of the major histocompatibility complex II (MHC class II)
in patients suffering from autoimmune and inflammatory diseases."

About Kalypsys
Kalypsys is a privately owned San Diego small-molecule drug company that
uses a suite of validated, ultra-high throughput lead discovery technologies
developed initially by the Genomics Institute of the Novartis Research
Foundation (GNF). There can be no assurance that any drug targets or
therapeutic entities will be discovered, that therapeutic entities will enter
clinical trials, that clinical trial results will be predictive for future
results, that therapeutic entities will be the subject of filings for
regulatory approval, that any drug candidates will receive marketing approval
from the U. The company assumes no responsibility to update forward-looking
statements or adapt them to future events or developments.

detrimental nexia

"In
addition to driving our own in-house small molecule pipeline, establishing
strategic partnerships is a key component of our business model.com

nexia sigrist

D.
"Generating a safe yet effective NCE is a significant challenge requiring
robustness , focus and innovative strategies.kalypsys.D.

About Medarex
Medarex is a biopharmaceutical company focused on the discovery and
development of fully human antibody-based therapeutics to treat life-
threatening and debilitating diseases, including cancer, inflammation,
autoimmune and infectious diseases.com.

For Medarex: Except for the historical information presented herein,
matters discussed herein may constitute forward-looking statements that are
subject to certain risks and uncertainties that could cause actual results to
differ materially from any future results, performance or achievements
expressed or implied by such statements.

silencing unfriendly

Kalypsys has an integrated drug discovery infrastructure
and seasoned team of scientists that are advancing its pipeline into clinical
development .

About NovImmune
NovImmune is a Geneva-based drug development company focusing on immune
related diseases, inflammation and immunosuppression.3434

NovImmune SA:
Jack Barbut, ScD.

Cytos Biotechnology and Medarex Expand Their Collaboration for New Drug Targets

"This new agreement gives us the opportunity to expand our work with Cytos
Biotechnology by accessing a broader range of disease targets discovered by
the DELphi(TM) technology ," said Donald L.

sandoz commercializing

com. For more information on
NovImmune, please visit http://www.
Mark Dyer, Executive VP, Business Development of Cytos Biotechnology,
comments: "The expanded agreement enables both companies to benefit from the
drug targets that we jointly discover through their use in generating Medarex
monoclonal antibodies and Cytos Biotechnology Immunodrugs(TM)."

About Cytos Biotechnology AG
Cytos Biotechnology AG is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new class
of biopharmaceutical products - the Immunodrugs(TM).
The Immunodrug(TM) candidates are developed both in-house (24) and together
with Novartis (1) and Pfizer Animal Health (2). Against the
background of these uncertainties readers should not rely on forward-looking
statements.

ligands biosensors

, Inc, the National
Institutes of Health and the Los Alamos National Laboratories.novimmune. Medarex is
committed to building value by developing a diverse pipeline of antibody
products to address the world's unmet healthcare needs.

sandoz biosensors

"We believe that NovImmune's expertise in the field of immunology
partnered with our technology and small molecule skills will add successful
collaboration candidates to the Kalypsys and NovImmune pipelines," stated John
McKearn, Ph.

Contacts: Kalypsys, Inc:
John Delyani, Ph. Immunodrugs(TM) are
intended for use in the treatment and prevention of common chronic diseases,
which afflict millions of people worldwide.

biosensors sandoz

Through this collaboration, Kalypsys and NovImmune are working to develop
therapeutics to target the cause of T lymphocyte-mediated autoimmune tissue
destruction and not simply its final consequences.546. Medarex also receives a first right of negotiation
for use of these targets in small molecule drug discovery and as protein
therapeutics . By integrating high throughput screening
and functional genomics, the parties believe that DELphi (TM) offers Cytos
Biotechnology's partners a competitive edge in the race for new drug targets.

phage biosensors

Its main products are
fully human therapeutic monoclonal antibodies, directed against well-validated
and medically relevant targets. Whilst the human genome sequence has been
completed, the formidable task of understanding the function of the proteins
encoded by the genes is underway.

phage silencing

839. (Nasdaq: MEDX)
announced today that the two companies have expanded the scope of their
collaborative research , development and license agreement for new drug
targets. Cytos Biotechnology
also retains rights to develop and commercialize the target proteins
discovered for its own Immunodrugs(TM). Risks and uncertainties include risks
associated with product discovery and development, uncertainties related to
the outcome of clinical trials, slower than expected rates of patient
recruitment, unforeseen safety issues resulting from the administration of
antibody products in patients, uncertainties related to product manufacturing,
risks associated with the use of hazardous substances as well as risks
detailed from time to time in Medarex's public disclosure filings with the
U.

synergene oligos

D.4811
holli.

detrimental polypeptides

ZURICH, Switzerland, and PRINCETON, N. Securities and Exchange Commission (SEC), including its Annual Report on
Form 10-K for the fiscal year ended December 31, 2004 and subsequent Quarterly
Reports on Form 10-Q. Copies of Medarex's
public disclosure filings are available from its investor relations
department.

phage transgenic

The NovImmune/Kalypsys
collaboration brings these to the table , synergizing the biology NovImmune
uses to develop first-line antibody therapeutics with Kalypsys ' powerful small
molecule engine," said Marie Kosco-Vilbois, Ph. In addition, NovImmune is
developing a new class of immunosuppressors and anti-inflammatory agents as
low molecular weight inhibitors of MHC Class II expression, directed against
highly specific and totally validated protein targets .754. Drakeman, President and CEO of
Medarex.S.

Medarex(R), the Medarex logo and UltiMAb (R) are registered trademarks of
Medarex, Inc.

Biotechnology refers to the use of cellular and molecular processes in drug discovery and manufacturing, research, and biologically engineered food production .

sigrist commercializing

The first agreement between the companies was announced in November
2002 and focused on drug targets for immunological diseases. These forward-looking statements are subject to a
variety of significant uncertainties, including scientific, business, economic
and financial factors, and therefore actual results may differ significantly
from those presented. This document does
not constitute an offer or invitation to subscribe or purchase any securities
of Cytos Biotechnology AG.

ligands ibt

, President and Chief Executive Officer of Kalypsys. Kalypsys may also participate in research and development of
identified leads. NovImmune will provide a proprietary assay in addition to
biology, pharmacology, and chemistry to support the research effort.858. Immunodrugs(TM) are designed to
instruct the patient's immune system to produce desired therapeutic antibody
or cytotoxic T-cell responses that modulate chronic disease processes. Founded in 1995 as a spin-off
from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is
located in Schlieren (Zurich).

The term also covers drug delivery systems and diagnostic compounds.

biosensors undifferentiated

This new
agreement expands the collaboration scope and will include drug targets
discovered in other disease areas of interest. Currently, the company has 110 employees .

ligands ibt

Cytos
Biotechnology AG has been listed on the SWX Swiss Exchange (SWX: CYTN) since
October 2002 . Twenty-two of these therapeutic products
derived from Medarex technology are currently in human clinical testing, with
the most advanced product presently in a Phase III clinical trial. For more information
about Medarex, visit its website at http://www. There can be no assurance that such development efforts
will succeed or that other developed products will receive required regulatory
clearance or that, even if such regulatory clearance were received, such
products would ultimately achieve commercial success. All rights are reserved.

sandoz oligos

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)